COR2ED’s Post

Exciting Progress in Prostate Cancer Treatment I'm thrilled to share new advancements in the field of metastatic prostate cancer therapy. Radioligand therapy (RLT) continues to be at the forefront of treatment innovation, and it is an honor to contribute to the advancement of research in 177Lu-PSMA-617, particularly in castration-resistant disease. This morning, Kim Chi from The The University of British Columbia presented compelling findings at the ESMO - European Society for Medical Oncology congress of 2024. The analysis focused on the hematologic adverse events of 177Lu-PSMA-617 compared to switching ARPIs in the phase III PSMAfore study. These results align with the safety profile observed in the VISION study, bringing us closer to more effective and safer treatments. A heartfelt thanks to all the dedicated members of the RLT team, the courageous patients, and their families for their invaluable contributions. Together, we are generating crucial knowledge that holds the promise of improved outcomes and quality of life for many. #ProstateCancer #MedicalInnovation #RadioligandTherapy #ESMO24 #177LuPSMA617 #CancerResearch #HealthcareHeroes

We are pleased to announce the establishment of a clinical implementation study with breast imaging centres across the United States—in New York, Miami and Houston. The initiative will pilot the integration of the geneType into breast imaging centres, assisting in the streamlining of care that is currently somewhat fragmented. It will be a significant step forward in personalised medicine, particularly in the context of breast density notification and supplemental screening options for those women at increased risk. By integrating the #geneType Breast Cancer Risk Assessment Test into breast imaging centres, patients at higher risk of breast cancer can be easily identified during imaging appointments. They can then be automatically triaged back into the supplementary screening process within the centre. This approach empowers patients to make better decisions about their screening options while ensuring a seamless transition within the centre's workflow. Ultimately, this study heralds a new era of precision medicine in the fight against breast cancer, providing screening and risk-reduction opportunities by identifying more at-risk individuals. Read the full release here👇 https://lnkd.in/gYJ_zQ_J #breastcancer #breastcancerscreening #womenshealth #precisionmedicine #populationhealth #breastdensity #GeneticTechnologies #GTG #GENE

Colon Cancer is a severe condition that requires the Best Treatment. It typically affects older adults, but early Colon Cancer detection can save lives. Dharan Cancer Specialty Centre is here to help you combat Colon Cancer using the latest cutting-edge technology. We employ state-of-the-art diagnostic techniques, such as advanced imaging and genetic testing, to identify any potential risks or signs of Colon Cancer. By combining innovative technologies and extensive research, we strive to provide top-notch care for our patients. Our highly experienced Oncologists are committed to providing the best quality care and offer a spectrum of treatments, including Chemotherapy, Radiation, Immunotherapy, Targeted therapy, and Surgical procedures. Take control of your health and schedule a consultation with our specialists at Dharan Cancer Specialty Centre. Together, let's beat Colon Cancer and reclaim your health! #treatmentforcoloncancer #rectumcancer #colorectalcancer #earlyscreening #coloncancer #cancertreatment #cancerpatients #cancercare #cancercentre #ComprehensiveCancerCare #colorectalcancerawareness #bowelcancer #ColorectalCancerScreening #coloncancer #chemotherapy #TargetedTherapy #RadiationTherapy #immunotherapy For Further Query #Call: +91 - 99439 39990 #Visit: https://lnkd.in/gY4mhra

Nasal and Sinus Cancer, a subtype of Head and Neck Cancer, originates in the tissue of the nose or sinuses. At Dharan Cancer Speciality Centre, we stand as a beacon of hope for those confronting this challenge, often linked to symptoms like persistent nosebleeds or nasal blockage—signs that should never be overlooked. With cutting-edge technology and a team of renowned Oncologists, we offer precise diagnostics and personalized treatment plans. From groundbreaking Radiation therapy to expert Surgical interventions, our multidisciplinary approach ensures every patient receives the highest standard of care. Timely detection and preemptive action are crucial in combating Cancer. If you experience persistent Nasal blockage, get screened for Nasal Cancer and safeguard your health by scheduling a screening today. #lossofsmell #nosebleeds #cancertreatment #cancerpatients #cancercare #cancercentre #ComprehensiveCancerCare #dharancancercare #nasalcare #sinusinfection #nasalandsinuscancer #sinuscancer #BestHospitality #getscreenedtoday #oncology #chemotherapy #nasalblockage #nasalandsinuscancer For Further Query #Call : +91 - 99439 39990 #Visit : https://lnkd.in/fqCzSnA

🔬🌟 Interesting Progress in Cancer Research! 🦠👩🔬 We are thrilled to announce the recent publication of a paper co-authored by our esteemed experts at BioReperia in collaboration with Linköping University. The paper entitled "Zebrafish Tumour Xenograft Models: A Prognostic Approach to Epithelial Ovarian Cancer" was published this week in npj Precision Oncology, a #Nature journal! DOI 10.1038/s41698-024-00550-9 Epithelial #ovariancancer (EOC)remains a challenging malignancy with high mortality rates. This #research presents a novel prognostic approach utilizing our #ZTX (#zebrafish #tumour #xenograft) model to assess treatment outcomes and #predict #patient #prognosis. Key Highlights: 🔬 Establishment of safe and efficacious doses of carboplatin and paclitaxel using IGROV-1 zebrafish-CDX models 🔍 Successful engraftment of #EOC patient-derived tumour xenografts in #zebrafishlarvae 💊 Assessment of #tumour #growth, #regression, and #metastaticdissemination in response to treatment with #carboplatin or #paclitaxel 📊 Correlation between ZTX model response to treatment and patient progression-free survival 💡 Potential for ZTX models to serve as a prognostic tool in EOC treatment planning These preliminary findings offer promising insights into #personalizedtreatment strategies for #epithelial ovarian cancer, highlighting the potential of our ZTX® platform in predicting patient outcomes and guiding therapeutic interventions. Please don’t miss the chance to read the full paper here: https://lnkd.in/gBKdibDT Let's continue to lead the way in cancer #research and make a difference in patients' lives!🎗️💪 #CancerResearch #PrecisionOncology #ZebrafishModels #EpithelialOvarianCancer #PrognosticApproach #OurCompanyResearch 

🔬 Celnovte's CK8&18 (C7E10/C6B9) Antibody Achieves Optimal Performance in NordiQC Assessment 🔬 ✅ Key usages of CK8&18 marker in IHC: - Identifying epithelial cells in various tissues. - Diagnosing carcinomas, including breast, colorectal, and lung cancers. - Differentiating between epithelial tumors and non-epithelial tumors. - Assessing metastatic carcinoma in lymph nodes and other tissues. - Investigating hepatocellular carcinoma and distinguishing it from other liver tumors. - Studying normal and malignant epithelial tissues in basic and clinical research. Enhance your research and diagnostic precision with the CK8&18 marker. #Pathology #IHC #Immunohistochemistry #CancerResearch #Carcinoma #BreastCancer #ColorectalCancer #LungCancer #HepatocellularCarcinoma #Immunology #CK8and18Marker #Celnovte #Histology #IHC

🚨 New Publication: Long-term Results of the GENEVIEVE Study     This year, the long-term results of an exciting Phase II study were published: the #GENEVIEVE study, comparing #cabazitaxel and #paclitaxel as #neoadjuvant #treatment in #patients with triple-negative or luminal B/HER2-negative breast cancer. 🔬 The study initially reported significant differences in pathological complete response (#pCR) rates between the two treatment arms. However, these differences did not significantly impact long-term outcomes, such as: 👉 Invasive disease-free survival (#iDFS) 👉 Distant disease-free survival (#DDFS) 👉 Overall survival (#OS) After a follow-up of nearly 90 months, no significant differences in 3- and 5-year #survival rates were observed between the two therapies. 🎗️ 💡 Conclusion: Despite significant differences in the pCR rates, no long-term survival benefits could be demonstrated after a median follow-up of 89.3 months. This highlights the complexity of prognosis in breast cancer. 📄 Find here the download link: https://lnkd.in/de64sCUj   GBG Forschungs GmbH #BreastCancerAwarenessMonth #Oncology #ClinicalTrials #ClinicalStudy #FollowUp #CancerTreatment #LongTermResults #NeoadjuvantTherapy #ESMOOpen #GBG

Just accepted our last review on Long COVID and cardio-oncology. An interesting analysis on the molecular interaction between White Adipose Tissue (rich in M1 macrophages and several lymphocytes with a Th1/Th17 phenotype), Cancer and Heart Tissue and the key role of myosteatosis in etiopathogenesis of myocardial diseases in cancer patients, affecting their risk of mortality. https://lnkd.in/df_cgtWq

This cross-sectional study finds substantial heterogeneity in the methods used to estimate kidney function for clinical trial eligibility for patients for enrollment in contemporary cancer RCTs. https://ja.ma/3BfjzQ1

Take a look at our latest scientific paper showing the translatability and predictability of the zebrafish tumor xenograft model to patient treatment outcome.